The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000018.4(ACADVL):c.751A>G (p.Ser251Gly)

CA10640460

324989 (ClinVar)

Gene: ACADVL
Condition: very long chain acyl-CoA dehydrogenase deficiency
Inheritance Mode: Autosomal recessive inheritance
UUID: 9e28ea5e-51c4-457d-b1a6-77bc36d3abed
Approved on: 2025-02-25
Published on: 2025-02-25

HGVS expressions

NM_000018.4:c.751A>G
NM_000018.4(ACADVL):c.751A>G (p.Ser251Gly)
NC_000017.11:g.7222080A>G
CM000679.2:g.7222080A>G
NC_000017.10:g.7125399A>G
CM000679.1:g.7125399A>G
NC_000017.9:g.7066123A>G
NG_007975.1:g.7247A>G
NG_008391.2:g.2971T>C
ENST00000356839.10:c.751A>G
ENST00000322910.9:c.*706A>G
ENST00000350303.9:c.685A>G
ENST00000356839.9:c.751A>G
ENST00000543245.6:c.820A>G
ENST00000577191.5:n.828A>G
ENST00000579286.5:n.932A>G
ENST00000580365.1:n.482A>G
ENST00000581378.5:c.469A>G
ENST00000582379.1:n.135A>G
ENST00000583760.1:n.533A>G
NM_000018.3:c.751A>G
NM_001033859.2:c.685A>G
NM_001270447.1:c.820A>G
NM_001270448.1:c.523A>G
NM_001033859.3:c.685A>G
NM_001270447.2:c.820A>G
NM_001270448.2:c.523A>G
More

Likely Pathogenic

Met criteria codes 4
PP3 PM3 PP4_Moderate PM2_Supporting

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
ACADVL VCEP
The NM_000018.4(ACADVL): c.751A>G (p.Ser251Gly) variant is a missense variant predicted to cause substitution of serine by glycine at amino acid 251. This variant has been detected in one individual with very long chain acyl CoA dehydrogenase (VLCAD) deficiency. This individual was compound heterozygous for the variant and a pathogenic variant and confirmed in trans by parental testing (1.0 PM3 points, PMID: 26937394, PM3_moderate). At least one patient with this variant displayed NBS C14:1 levels ≥ 1.0 μM and follow-up Plasma Acylcarnitine analysis consistent with VLCADD, which is highly specific for VLCAD deficiency (PP4_moderate, PMID: 26937394). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003 in the non-Finnish European population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.978, which is above the threshold of 0.75, evidence that correlates with impact to ACADVL function (PP3). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal recessive VLCAD deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: PM2_Supporting, PM3_moderate, PP3, PP4_Moderate (ACADVL VCEP specifications version 1; approved November 9, 2021).
Met criteria codes
PP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM3
1.0 point
PP4_Moderate
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM2_Supporting
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.